La Jolla's drug development efforts are focused on two product candidates: GCS-100 and LJPC-501. Our lead product, GCS-100, focuses on modulation of galectin-3, a member of the galectin family of proteins. Over-expression of galectin-3 has been implicated in chronic organ failure and cancer. GCS-100 is currently being evaluated in patients with chronic kidney disease. Our second product candidate, LJPC-501,is a peptide agonist of the renin-angiotensin system that acts to help the kidneys balance body fluids and electrolytes. Studies have shown that LJPC-501 may improve renal function in patients with hepatorenal syndrome (HRS), a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure. We have an active IND to evaluate LJPC-501 in patients with hepatorenal syndrome and plan to initiate a clinical study in the 3rd quarter of 2013. In addition to GCS-100 and LJPC-501, our scientists are researching the development of a subcutaneous formulation of GCS-100 (LJPC-101), synthetic galectin antagonists (LJPC-201), biological galectin antagonists (LJPC-301) as well as continuously evaluating new opportunities for the treatment of unmet medical needs.